XYZ-I-73

XYZ-I-73 is a novel small molecule 5-fluorouracil (5-FU) analog developed by researchers at Florida A&M University for the treatment of pancreatic cancer. The compound is synthesized by modifying 5-fluorocytosine with a tetrahydrofuran ring and conjugating it with lauroyl chloride, a modification designed to enhance metabolic stability and cytotoxic potency. Preclinical evaluations in MiaPaCa-2, PANC-1, and BxPC-3 pancreatic cancer cell lines demonstrated that XYZ-I-73 possesses superior antiproliferative activity compared to standard-of-care agents such as 5-FU, gemcitabine, and irinotecan. Its mechanism of action involves the inhibition of PARP expression and the induction of apoptosis through the upregulation of BAX and p53. Furthermore, XYZ-I-73 exhibits improved stability in human liver microsomes, potentially overcoming the rapid metabolic degradation typically observed with conventional fluoropyrimidines.

Other names

lauroyl-5-fluorocytosine-tetrahydrofuran analoglauroyl5-fluorocytosine-tetrahydrofuran analoglauroyl 5-fluorocytosine-tetrahydrofuran analog